Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer

2013 ◽  
Vol 2 (3) ◽  
pp. 243-263 ◽  
Author(s):  
Cristina Santos ◽  
Eduardo Vilar ◽  
Gabriel Capella ◽  
Ramon Salazar
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Molecular Markers ◽  
Clinical Relevance ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Susie Bae ◽  
Hui-Li Wong ◽  
Jeanne Tie ◽  
Jayesh Desai ◽  
Kathryn Field ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Recurrence ◽  
Population Based ◽  
Stage Ii ◽  
Diabetes Status ◽  
Stage Ii Colon Cancer ◽  
Diabetes Patients

Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5–101.2). The diabetes patients (21.6%,n= 241) were older than nondiabetes patients (median 74.0 versus 69.6,p= 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%,p= 0.002) but were equally likely to complete treatment (69.7 versus 67.7%,p= 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71–1.63) or overall survival (HR = 1.23, 95% CI 0.88–1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer.

scholarly journals Prognostic value of clinical, pathological and immunohistochemical markers in stage II colon cancer patients

2008 ◽  
Vol 55 (3) ◽  
pp. 39-44 ◽  
Author(s):  
Z. Stor ◽  
G.S. Frkovic ◽  
M. Bracko ◽  
S. Repse
Keyword(s):  
Colon Cancer ◽  
Molecular Markers ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Perineural Invasion ◽  
Histological Grade ◽  
Tnm Stage ◽  
Stage Ii ◽  
Immunohistochemical Markers ◽  
Stage Ii Colon Cancer

Background/Aims: The purpose of our analysis was to determine the prognostic value of molecular markers for identifying high-risk TNM stage II colon cancer patients, the association with various clinical and pathological features, and possible relation to survival. Methods: In 191 colon cancer patients who underwent a potentially curative resection, clinical and pathological factors (age, tumour site, histological grade of malignancy, pT stage, presence of venous, lymphatic and perineural invasion) and tumour molecular markers were analyzed. Molecular markers were assessed immunohistochemically in sections of paraffin- embedded tissues. Patients were followed for a median of 8.7 years. The 5-year survival rate was estimated using the Kaplan-Meier statistical method. Results: From 1. Jan.1994 to 31.Dec.2000, 191 patients underwent radical resection for T3-4 N0M0 colorectal cancer without adjuvant chemotherapy. A significant decrease in survival was identified in older patients, patients with tumours pT4 and with perineural invasion. We found no significant differences in survival of patients with expression of MLH1, Cyclin D1 and reduced overexpression of E-cadherin. Conclusions: The results of our study indicate that the presence of perineural invasion, pT4 stage and the patient?s age are significantly correlated with the expected survival in radically resected TNM stage II colon cancer patients, while immunohistochemical markers are not related to survival.

CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer

2019 ◽  
Vol 90 ◽  
pp. 70-79
Author(s):  
Matthew J. Cecchini ◽  
Joanna C. Walsh ◽  
Jeremy Parfitt ◽  
Subrata Chakrabarti ◽  
Rohann J. Correa ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Markers ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhihao Lv ◽  
Yuqi Liang ◽  
Huaxi Liu ◽  
Delong Mo
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Prediction Models ◽  
Radical Surgery ◽  
Survival Rates ◽  
Stage Ii ◽  
Survival Prediction ◽  
Stage Ii Colon Cancer ◽  
Overall Survival Rates

Abstract Background It remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy. Methods Data for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves. Results A total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration. Conclusions Chemotherapy improves the short-term (43 months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

scholarly journals Adjuvant therapy for stage II colon cancer: an elephant in the living room?

2004 ◽  
Vol 15 (9) ◽  
pp. 1310-1318 ◽  
Author(s):  
A. Zaniboni ◽  
R. Labianca
Keyword(s):  
Colon Cancer ◽  
Adjuvant Therapy ◽  
Stage Ii ◽  
Living Room ◽  
Stage Ii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document